Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 5, 2002, Pages 467-474

  Wu, Kendall ^a   Rodriquez, Jenny L ^b   Hilsenbeck, Susan G ^a   Mohsin, Syed K ^a   Xu, Xiao Chun ^c   Lamph, William W ^d   Kuhn, John G ^b   Green, Jeff E ^e   Brown, Powel H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d LIGAND PHARMACEUTICALS INC   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; VIRUS T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER PREVENTION; CANCER SIZE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; ERYTHEMA; FEMALE; GROWTH INHIBITION; HAIR LOSS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT PLANNING;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BENZOATES; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH INHIBITORS; HISTONES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS; SENSITIVITY AND SPECIFICITY; TETRAHYDRONAPHTHALENES; TIME FACTORS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0036094845     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Cancer statistics, 2000
2. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-Study
3. The effect of raloxifene on risk of breast cancer in postmenopausal women-results from the MORE randomized trial
4. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial
5. Cancer chemoprevention part 2: Hormones, nonclassic antioxidant natural agents. NSAIDs, and other agents
6. Cancer chemoprevention part 1: Retinoids and carotenoids and other classic antioxidants
7. Cellular biology and biochemistry of the retinoids
8. Cellular biology and biochemistry of retinoids
9. Role of retinoid receptors in the prevention and treatment of breast cancer
10. Nuclear hormone receptors and gene expression
11. Retinoids in embryonal development
12. Induction of retinoid resistance in breast cancer cells by overexpression of cJun
13. Activation of three distinct RXR/RAR heterodimers induces growth arrest and differentiation of neuroblastoma cells
14. Effects of novel retinoid X receptor-selective ligands on myeloid leukemic differentiation and proliferation in vitro
15. 9-cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein
16. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen
17. 9-cis retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T-antigen transgenic mice
18. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid
19. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: Ductal epithelial cell targeting with multistage progression to carcinoma
20. Differential expression of retinoic acid receptors and p53 protein in normal, premalignant and malignant esophageal tissues
21. Multiple factors contribute to the toxicity of the aromatic retinoid. TTNPB (Ro 13-7410): Binding affinities and disposition
22. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids
23. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand
24. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations
25. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer
26. Tamoxifen and fenretinide in women with metastatic breast cancer
27. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid
28. Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma
29. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069
30. A Phase I study of LGD1069 in adults' with advanced cancer
31. Bexarotene ligand pharmaceuticals